Idroquark

Hydrochlorothiazide and Ramipril, the active ingredient in Idroquark, is a thiazide diuretic / ACE inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of hypertension and edema associated with hypertension in adult patients. GNH USA supplies Idroquark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Idroquark combines a thiazide diuretic and an ACE inhibitor to lower elevated blood pressure and reduce fluid overload. - Hypertension: provides sustained reduction of systolic and diastolic blood pressure, helping to achieve target levels recommended by clinical guidelines. - Edema associated with hypertension: promotes diuresis to decrease extracellular fluid volume, relieving swelling while concurrently controlling blood pressure. - Cardiovascular risk reduction: contributes to lower incidence of hypertension‑related complications by maintaining long‑term blood‑pressure control.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after the first doses. - Cough: dry, persistent throat irritation linked to ACE‑inhibitor activity. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway requiring immediate medical attention. - Severe allergic reaction: rash, itching, or anaphylaxis. - Hyperkalemia: dangerously high potassium levels, especially when combined with potassium‑sparing agents. - Acute kidney injury: sudden decline in renal function. - Severe dehydration: excessive fluid loss leading to hypotension. - Hepatic dysfunction: rare liver enzyme elevations.

Before initiating therapy, clinicians should assess patient suitability and monitor relevant parameters. - Blood pressure monitoring: ensure adequate control and avoid hypotension. - Renal function assessment: check serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte surveillance: monitor potassium and sodium levels regularly. - Caution in diabetes: watch for changes in blood‑glucose control. - Avoid use in severe renal impairment: dose adjustment may be required or therapy contraindicated. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Idroquark may interact with several medicines, requiring careful management. Major Interactions (Avoid): - Aliskiren: concurrent use with ACE inhibitors can increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous elevations in serum potassium. - Lithium: increased lithium levels and risk of toxicity. Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function. - Other antihypertensives (e.g., beta‑blockers): may enhance blood‑pressure lowering, requiring dose adjustments.